eHealth, Inc.
NASDAQ:EHTHInsurance - Brokers
-$0.05 today
- Market cap
- $50.15M
- Beta
- 1.48
- P/E (TTM)
- 1.5
- EPS (TTM)
- $1.08
Volume 0.31M
Average 0.46M
EHTH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
eHealth, Inc.NASDAQ: EHTH
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $3.46M a year earlier. Trailing-twelve-month research & development was $7.89M.
Context
- Research & development amounted to 9.4% of revenue in FY2025, up 9.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.97M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 51.83M USD
- Year-over-year change
- —
- 4-year CAGR
- -11.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.83M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 83.8M | — |
Research & Development vs competitors
How EHTH compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 1.5% of revenue for EHTH, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.89M USD | -58.9% | — | 1.5% | |
| LTM Mar 2026 | CN¥0 CNY | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding EHTH) | — | — | — | 0.0% | |
Competitors are the stored peer set for EHTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.2M | 405.36M | 452.87M | 532.41M | 554.01M |
| Cost of Revenue | 1.99M | 1.65M | 1.77M | 1.79M | 13.76M |
| Gross Profit | 536.21M | 403.71M | 451.1M | 530.62M | 540.25M |
| Gross Margin | 99.6% | 99.6% | 99.6% | 99.7% | 97.5% |
| Research & Development | 83.8M | 0 | 0 | 0 | 51.83M |
| Selling, General & Admin | 347M | 266.9M | 272M | 280.6M | 270.8M |
| Operating Expenses | 661.85M | 506.42M | 480.17M | 507.05M | 471.75M |
| Depreciation & Amortization | 18.87M | 21.11M | 19.92M | 16.34M | 13.76M |
| EBITDA | (105.18M) | (77.65M) | 295K | 46.81M | 83.25M |
| EBITDA Margin | -19.5% | -19.2% | 0.1% | 8.8% | 15.0% |
| Operating Income | (125.65M) | (102.71M) | (29.07M) | 23.57M | 68.5M |
| Operating Margin | -23.3% | -25.3% | -6.4% | 4.4% | 12.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 845K | 7.63M | 10.97M | 11.16M | 10.76M |
| Other Income / Expenses | 755K | (3.68M) | (1.52M) | (4.26M) | (9.77M) |
| Income Before Tax | (124.89M) | (106.39M) | (30.6M) | 19.31M | 58.73M |
| Pre-Tax Margin | -23.2% | -26.2% | -6.8% | 3.6% | 10.6% |
| Income Tax Expense | (20.52M) | (17.67M) | (2.38M) | 9.26M | 18.68M |
| Net Income | (104.38M) | (88.72M) | (28.21M) | 10.06M | 40.04M |
| Net Margin | -19.4% | -21.9% | -6.2% | 1.9% | 7.2% |
| EPS (Basic) | (4.59) | (4.36) | (2.37) | (1.19) | (0.34) |
| EPS (Diluted) | (4.59) | (4.36) | (2.37) | (1.19) | (0.34) |
| Weighted Avg Shares | 26.78M | 27.36M | 28.02M | 29.34M | 30.48M |
| Weighted Avg Shares (Diluted) | 26.78M | 27.36M | 28.02M | 29.34M | 30.48M |
eHealth, Inc.
NASDAQ:EHTH
Intrinsic Alpha fair value
Locked
Current Price
$1.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.